Interaction of the n-(3-methylpyridin-2-yl) amide derivatives of flurbiprofen and ibuprofen with faah: Enantiomeric selectivity and binding mode

PLoS ONE

Volumn 10, Issue 11, 2015, Pages

  Karlsson, Jessica ^a   Morgillo, Carmine M ^b   Deplano, Alessandro ^c   Smaldone, Giovanni ^d   Pedone, Emilia ^d   Luque, F Javier ^e   Svensson, Mona ^a   Novellino, Ettore ^b   Congiu, Cenzo ^c   Onnis, Valentina ^c   Catalanotti, Bruno ^b   Fowler, Christopher J ^a  

^a UMEÅ UNIVERSITY   (Sweden)

^b UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^c UNIVERSITY OF CAGLIARI   (Italy)

^d CNR   (Italy)

^e UNIVERSITY OF BARCELONA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

2 (4 ISOBUTYLPHENYL) N (3 METHYLPYRIDIN 2 YL)ACETAMIDE; 2 (4 ISOBUTYLPHENYL) N (3 METHYLPYRIDIN 2 YL)PROPANAMIDE; AMIDE; CARPROFEN; FATTY ACID AMIDASE; FLURBIPROFEN; IBUPROFEN; N (3 METHYLPYRIDIN 2 YL)AMIDE DERIVATIVE; UNCLASSIFIED DRUG; AMIDASE; AMINOPYRIDINE DERIVATIVE; FATTY-ACID AMIDE HYDROLASE; FLURBIPROFEN 2-AMINO-3-METHYLPYRIDINE AMIDE; IBUPROFEN 2-AMINO-3-METHYLPYRIDINE AMIDE; PROSTAGLANDIN SYNTHASE; PROSTAGLANDIN SYNTHASE INHIBITOR; PROTEIN BINDING; RECOMBINANT PROTEIN;

ADULT; ANIMAL TISSUE; ARTICLE; BINDING AFFINITY; CHIRALITY; CONTROLLED STUDY; DRUG BINDING SITE; DRUG IDENTIFICATION; DRUG PROTEIN BINDING; DRUG SELECTIVITY; DRUG STRUCTURE; ENANTIOMER; ENZYME INHIBITION; ENZYME SPECIFICITY; ENZYME SUBSTRATE COMPLEX; MALE; MOLECULAR DOCKING; MOLECULAR DYNAMICS; MOUSE; NONHUMAN; RAT; ANALOGS AND DERIVATIVES; ANIMAL; ANTAGONISTS AND INHIBITORS; BRAIN; CHEMISTRY; DRUG DESIGN; ENZYMOLOGY; HELA CELL LINE; HUMAN; HYDROLYSIS; IC50; KINETICS; METABOLISM; SPRAGUE DAWLEY RAT; STEREOISOMERISM; WISTAR RAT;

AMIDOHYDROLASES; AMINOPYRIDINES; ANIMALS; BRAIN; CYCLOOXYGENASE INHIBITORS; DRUG DESIGN; FLURBIPROFEN; HELA CELLS; HUMANS; HYDROLYSIS; IBUPROFEN; INHIBITORY CONCENTRATION 50; KINETICS; MALE; MICE; MOLECULAR DYNAMICS SIMULATION; PROSTAGLANDIN-ENDOPEROXIDE SYNTHASES; PROTEIN BINDING; RATS; RATS, SPRAGUE-DAWLEY; RATS, WISTAR; RECOMBINANT PROTEINS; STEREOISOMERISM;

EID: 84958817302     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0142711     Document Type: Article

References (44)

1. Bracey M, Hanson M, Masuda K, Stevens R, Cravatt B. Structural adaptions in a membrane enzyme that terminates endocannabinoid signaling. Science. 2002; 298:1793-6. PMID: 12459591
2. McKinney M, Cravatt B. Evidence for distinct roles in catalysis for residues of the serine-serine-lysine catalytic triad of fatty acid amide hydrolase. J Biol Chem. 2003; 278:37393-8399. PMID: 12734197
3. Palermo G, Campomanes P, Cavalli A, Rothlisberger U, De Vivo M. Anandamide hydrolysis in FAAH reveals a dual strategy for efficient enzyme-assisted amide bond cleavage via nitrogen inversion. J Phys Chem B. 2015; 119:789-801. doi: 10.1021/jp5052276 PMID: 25205244
4. Mor M, Rivara S, Lodola A, Plazzi P, Tarzia G, Duranti A, et al. Cyclohexylcarbamic acid 3-or 4'-substituted biphenyl-3-yl esters as fatty acid amide hydrolase inhibitors: synthesis, quantitative structureactivity relationships, and molecular modelling studies. J Med Chem. 2004; 47:4998-5008. PMID: 15456244
5. Alexander J, Cravatt B. Mechanisms of carbamate inactivation of FAAH: implications for the design of covalent inhibitors and in vivo functional probes for enzymes. Chem Biol. 2005; 12:1179-87. PMID: 16298297
6. Mei G, Di Venere A, Gasperi V, Nicolai E, Masuda K, Finazzi-Agrò A, et al. Closing the gate to the active site. Effect of the inhibitor methoxyarachidonyl fluorophosphonate on the conformation and membrane binding of fatty acid amide hydrolase. J Biol Chem. 2007; 282:3829-36. PMID: 17158103
7. Mileni M, Johnson D, Wang Z-Q, Everdeen D, Liimatta M, Pabst B, et al. Structure-guided inhibitor design for human FAAH by interspecies active site conversion. Proc Natl Acad Sci USA. 2008; 105:12820-4. doi: 10.1073/pnas.0806121105 PMID: 18753625
8. Myllymäki MJ, Käsnänen H, Kataja AO, Lahtela-Kakkonen M, Saario SM, Poso A, et al. Chiral 3-(4,5-dihydrooxazol-2-yl)phenyl alkylcarbamates as novel FAAH inhibitors: Insight into FAAH enantioselectivity by molecular docking and interaction fields. Eur J Med Chem. 2009; 44:4179-91. doi: 10.1016/j. ejmech.2009.05.012 PMID: 19539407
9. Hart T, Macias AT, Benwell K, Brooks T, D'Alessandro J, Dokurno P, et al. Fatty acid amide hydrolase inhibitors. Surprising selectivity of chiral azetidine ureas. Bioorg Med Chem Lett. 2009; 19:4241-4. doi: 10.1016/j.bmcl.2009.05.097 PMID: 19515560
10. Gustin DJ, Ma Z, Min X, Li Y, Hedberg C, Guimaraes C, et al. Identification of potent, noncovalent fatty acid amide hydrolase (FAAH) inhibitors. Bioorg Med Chem Lett. 2011; 21:2492-6. doi: 10.1016/j.bmcl. 2011.02.052 PMID: 21392988
11. Bertolacci L, Romeo E, Veronesi M, Magotti P, Albani C, Dionisi M, et al. A binding site for nonsteroidal anti-inflammatory drugs in fatty acid amide hydrolase. J Am Chem Soc. 2013; 135:22-5. doi: 10.1021/ja308733u PMID: 23240907
12. Otrubova K, Brown M, McCormick MS, Han GW, O'Neal ST, Cravatt BF, et al. Rational design of fatty acid amide hydrolase inhibitors that act by covalently bonding to two active site residues. J Am Chem Soc. 2013; 135:6289-99. doi: 10.1021/ja4014997 PMID: 23581831
13. Patel JZ, Parkkari T, Laitinen T, Kaczor AA, Saario SM, Savinainen JR, et al. Chiral 1,3,4-oxadiazol-2-ones as highly selective FAAH inhibitors. J Med Chem. 2013; 56:8484-96. doi: 10.1021/jm400923s PMID: 24083878
14. Palermo G, Rothlisberger U, Cavalli A, De Vivo M. Computational insights into function and inhibition of fatty acid amide hydrolase. Eur J Med Chem. 2015; 91:15-26. doi: 10.1016/j.ejmech.2014.09.037 PMID: 25240419
15. Paria B, Deutsch D, Dey S. The uterus is a potential site for anandamide synthesis and hydrolysis: differential profiles of anandamide synthase and hydrolase activities in the mouse uterus during the periimplantation period. Mol Reprod Dev. 1996; 45:183-92. PMID: 8914076
16. Fowler C, Tiger G, Stenström. Ibuprofen inhibits rat brain deamidation of anandamide at pharmacologically relevant concentrations. Mode of inhibition and structure-activity relationship. J Pharmacol Exp Ther. 1997; 283:729-34. PMID: 9353392
17. Fowler CJ, Janson U, Johnson RM, Wahlström G, Stenström A, Norström Å, et al. Inhibition of anandamide hydrolysis by the enantiomers of ibuprofen, ketorolac, and flurbiprofen. Arch Biochem Biophys. 1999; 362:191-6. PMID: 9989926
18. Favia AD, Habrant D, Scarpelli R, Migliore M, Albani C, Bertozzi SM, et al. Identification and characterization of carprofen as a multitarget fatty acid amide hydrolase/cyclooxygenase inhibitor. J Med Chem. 2012; 55:8807-26. doi: 10.1021/jm3011146 PMID: 23043222
19. Holt S, Paylor B, Boldrup L, Alajakku K, Vandevoorde S, Sundström A, et al. Inhibition of fatty acid amide hydrolase, a key endocannabinoid metabolizing enzyme, by analogues of ibuprofen and indomethacin. Eur J Pharmacol. 2007; 565:26-36. PMID: 17397826
20. De Wael F, Muccioli GG, Lambert DM, Sergent T, Schneider Y-J, Rees J-F, et al. Chemistry around imidazopyrazine and ibuprofen: discovery of novel fatty acid amide hydrolase (FAAH) inhibitors. Eur J Med Chem. 2010; 45:3564-74. doi: 10.1016/j.ejmech.2010.04.040 PMID: 20570023
21. Fowler CJ, Björklund E, Lichtman AH, Naidu PS, Congiu C, Onnis V. Inhibitory properties of ibuprofen and its amide analogues towards the hydrolysis and cyclooxygenation of the endocannabinoid anandamide. J Enzyme Inhib Med Chem. 2013; 28:172-82. doi: 10.3109/14756366.2011.643304 PMID: 22225576
22. Cipriano M, Björklund E, Wilson AA, Congiu C, Onnis V, Fowler CJ. Inhibition of fatty acid amide hydrolase and cyclooxygenase by the N-(3-methylpyridin-2-yl)amide derivatives of flurbiprofen and naproxen. Eur J Pharmacol. 2013; 720:383-90. doi: 10.1016/j.ejphar.2013.09.065 PMID: 24120370
23. Cocco M, Congiu C, Onnis V, Morelli M, Cauli O. Synthesis of ibuprofen heterocyclic amides and investigation of their analgesic and toxicological properties. Eur J Med Chem. 2003; 38:513-8. PMID: 12767601
24. Naidu P, Booker L, Cravatt B, Lichtman A. Synergy between enzyme inhibitors of fatty acid amide hydrolase and cyclooxygenase in visceral nociception. J Pharmacol Exp Ther. 2009; 329:48-56. doi: 10.1124/jpet.108.143487 PMID: 19118134
25. Sasso O, Migliore M, Habrant D, Armirotti A, Albani C, Summa M, et al. Multitarget fatty acid amide hydrolase/cyclooxygenase blockade suppresses intestinal inflammation and protects against nonsteroidal anti-inflammatory drug-dependent gastrointestinal damage. FASEB J. 2015; 29:2616-27. doi: 10.1096/fj.15-270637 PMID: 25757568
26. Gouveia-Figueira S, Karlsson J, Deplano A, Hashemian S, Svensson M, Fredriksson Sundbom M, et al. Characterisation of (R)-2-(2-fluorobiphenyl-4-yl)-N-(3-methylpyridin-2-yl)propanamide as a dual fatty acid amide hydrolase: cyclooxygenase inhibitor. PLoS ONE. 2015; 10:e0139212 doi: 10.1371/journal.pone.0139212 PMID: 26406890
27. Bradford MM. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem. 1976; 72:248-54. PMID: 942051
28. Boldrup L, Wilson SJ, Barbier AJ, Fowler CJ. A simple stopped assay for fatty acid amide hydrolase avoiding the use of a chloroform extraction phase. J Biochem Biophys Methods. 2004; 60:171-7. PMID: 15262451
29. Morris GM, Huey R, Lindstrom W, Sanner MF, Belew RK, Goodsell DS, et al. Autodock4 and Auto-DockTools4: automated docking with selective receptor flexiblity. J Comput Chem. 2009; 16:2785-91.
30. Gustin DJ, Ma Z, Min X, Li Y, Hedberg C, Guimaraes C, et al. (2011). Identification of potent, noncovalent fatty acid amide hydrolase (FAAH) inhibitors. Bioorg Med Chem Lett. 2011; 21:2492-6. doi: 10. 1016/j.bmcl.2011.02.052 PMID: 21392988
31. Case DA, Darden TA, Cheatham TE III, Simmerling CL, Wang J, Duke RE, et al. AMBER 12, University of California, San Francisco, 2012.
32. Lindorff-Larsen K, Piana S, Palmo K, Maragakis P, Klepeis JL, Dror RO, et al. Improved side-chain torsion potentials for the Amber ff99SB protein force field. Proteins. 2010; 78:1950-8. doi: 10.1002/prot. 22711 PMID: 20408171
33. Wang J, Wolf RM, Caldwell JW, Kollman PA, Case DA. Development and testing of a general amber force field. J Comput Chem. 2004; 25:1157-74. PMID: 15116359
34. Bayly CI, Cieplak P, Cornell WD, Kollman PA (1993). A well-behaved electrostatic potential based method using charge restraints for deriving atomic charges J Phys Chem. 1993; 97:10269-80.
35. Gaussian 09, Revision D.01, Frisch MJ, Trucks GW, Schlegel HB, Scuseria GE, Robb MA, Cheeseman JR, et al. Gaussian, Inc., Wallingford CT, USA, 2009.
36. Biasini M, Bienert S, Waterhouse A, Arnold K, Studer G, Schmidt T, et al. SWISS-MODEL: modelling protein tertiary and quaternary structure using evolutionary information. Nucleic Acids Res. 2014; 42: W252-8. doi: 10.1093/nar/gku340 PMID: 24782522
37. Motulsky HJ, Brown RE. Detecting outliers when fitting data with nonlinear regression-a new method based on robust nonlinear regression and the false discovery rate. BMC Bioinformatics. 2006; 7:123. PMID: 16526949
38. Dixon M. The determination of enzyme inhibitor constants. Biochem J. 1953; 55:170-1. PMID: 13093635
39. Segel IH. Enzyme kinetics. Behavior and analysis of rapid equilibrium and steady-state enzyme systems. Jhn Wiley & Sons, New York, 1975.
40. Eisenthal R, Cornish-Bowden A. The direct linear plot. A new graphical procedure for estimating enzyme kinetic parameters. Biochem J. 1974; 139:715-20. PMID: 4854723
41. Blat Y. Non-competitive inhibition by active site binders. Chem Biol Drug Des. 2010; 75:535-40. doi: 10.1111/j.1747-0285.2010.00972.x PMID: 20374252
42. Rome LH, Lands WEM. Structural requirements for time-dependent inhibition of prostaglandin biosynthesis by anti-inflammatory drugs. Proc Natl Acad Sci USA. 1975; 72:4863-5. PMID: 1061075
43. Estiarte MA, Johnson RJ, Kaub CJ, Gowlugari S, O'Mahony DJR, Nguyen MT, et al. 2-Amino-5-arylbenzoxazole derivatives as potent inhibitors of fatty acid amide hydrolase (FAAH). Med Chem Commun. 2012; 3:611-9.
44. Fowler CJ, Naidu PS, Lichtman A, Onnis V. The case for the development of novel analgesic agents targeting both fatty acid amide hydrolase and either cyclooxygenase or TRPV1. Br J Pharmacol. 2009; 156:412-9. doi: 10.1111/j.1476-5381.2008.00029.x PMID: 19226258